India’s Biocon Limited, signed a semi-exclusive partnership agreement with Zentiva, a leading pharmaceutical company in Europe, for the commercialization of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.
Under the terms of this agreement, Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva for sale across 30 countries in Europe. Biocon will also retain the right to commercialize this product under its own brand in the region.
Zentiva has a strong legacy in branded generics across several therapeutic areas, including diabetes, cardiology, respiratory and oncology. With a committed focus on research and development, and four flagship manufacturing facilities in Bucharest, Prague and Ankleshwar in Gujarat India, Zentiva is expanding its reach in Europe and beyond.
Siddharth Mittal, CEO and managing director, Biocon Ltd, said, “We are pleased to build upon our existing relationship with Zentiva for the commercialization of this complex drug product in the European markets. We look forward to leveraging our mutual strengths to achieve a common objective of creating affordable access to complex generic medicines.”
Last updated: December 26th, 2025
